简报:KRASG12C突变肺癌中序贯抗程序性细胞死亡(配体)1治疗与索托拉西布治疗相关的严重索托拉西布相关肝毒性及非肝脏不良事件
这项多中心回顾性研究纳入16家法国医疗中心临床试验外接受索托拉西布的102例晚期KRASG12C突变NSCLC患者,比较序贯组(48例,末线抗PD-(L)1后使用索托拉西布)与对照组(54例)。序贯组严重索托拉西布相关不良事件(50% vs 13%,p<0.001)、严重肝毒性(33% vs 11%,p=0.006)及非肝脏严重不良事件(27% vs 4%,p<0.001)均显著更常见。作者建议末次抗PD-(L)1输注后30天内避免启动索托拉西布。
要点
- 序贯组严重索托拉西布相关不良事件发生率为50%(24/48),对照组为13%(p<0.001)。
- 序贯组严重索托拉西布相关肝毒性发生率为33%,对照组为11%(p=0.006)。
- 序贯组非肝脏严重索托拉西布相关不良事件发生率为27%,对照组为4%(p<0.001)。
核心结论
- 序贯抗PD-(L)1后使用索托拉西布与严重索托拉西布相关肝毒性及严重非肝脏不良事件风险显著增加相关。
- 作者建议末次抗PD-(L)1输注后30天内避免启动索托拉西布。
研究设计与样本
- 多中心回顾性研究,纳入16家法国医疗中心临床试验外接受索托拉西布的连续晚期KRASG12C突变NSCLC患者。
- 共纳入102例患者,序贯组48例(47%),对照组54例(53%)。
- 序贯组定义为索托拉西布启动前末线治疗为抗PD-(L)1;对照组定义为索托拉西布启动前末线治疗非抗PD-(L)1。
- 对照组中87%的患者在索托拉西布前接受过抗PD-(L)1并后续至少一线治疗,13%从未接受抗PD-(L)1。
- 不良事件按美国国家癌症研究所不良事件通用术语标准第5.0版评定,≥3级为严重。
主要发现
- 序贯组严重索托拉西布相关不良事件发生率为50%(24/48),对照组为13%(p<0.001)。
- 序贯组24例严重不良事件患者中16例(67%)发生严重索托拉西布相关肝毒性。
- 序贯组严重索托拉西布相关肝毒性发生率为33%,对照组为11%(p=0.006)。
- 序贯组非肝脏严重索托拉西布相关不良事件发生率为27%,对照组为4%(p<0.001)。
- 未报告致死性索托拉西布相关肝毒性;严重不良事件典型发生于索托拉西布启动前30天内接受末次抗PD-(L)1输注的患者。
临床怎么用
- 作者建议末次抗PD-(L)1输注后30天内避免启动索托拉西布。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Sequential anti-programmed cell death protein 1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) followed by small targeted therapy use is associated with increased prevalence of adverse events (AEs) in NSCLC. KRASG12C inhibitor sotorasib may trigger severe immune-mediated hepatotoxicity when used in sequence or in combination with anti-PD-(L)1. This study was designed to address whether sequential anti-PD-(L)1 and sotorasib therapy increases the risk of hepatotoxicity and other AEs. METHODS: This is a multicenter, retrospective study of consecutive advanced KRASG12C-mutant NSCLC treated with sotorasib outside clinical trials in 16 French medical centers. Patient records were reviewed to identify sotorasib-related AEs (National Cancer Institute Common Classification Criteria for Adverse Events-Version 5.0). Grade 3 and higher AE was considered as severe. Sequence group was defined as patients who received an anti-PD-(L)1 as last line of treatment before sotorasib initiation and control group as patients who did not receive an anti-PD-(L)1 as last line of treatment before sotorasib initiation. RESULTS: We identified 102 patients who received sotorasib, including 48 (47%) in the sequence group and 54 (53%) in the control group. Patients in the control group received an anti-PD-(L)1 followed by at least one treatment regimen before sotorasib in 87% of the cases or did not receive an anti-PD-(L)1 at any time before sotorasib in 13% of the cases. Severe sotorasib-related AEs were significantly more frequent in the sequence group compared with those in the control group (50% versus 13%, p < 0.001). Severe sotorasib-related AEs occurred in 24 patients (24 of 48, 50%) in the sequence group, and among them 16 (67%) experienced a severe sotorasib-related hepatotoxicity. Severe sotorasib-related hepatotoxicity was threefold more frequent in the sequence group compared with that in the control group (33% versus 11%, p = 0.006). No fatal sotorasib-related hepatotoxicity was reported. Non-liver severe sotorasib-related AEs were significantly more frequent in the sequence group (27% versus 4%, p < 0.001). Severe sotorasib-related AEs typically occurred in patients who received last anti-PD-(L)1 infusion within 30 days before sotorasib initiation. CONCLUSIONS: Sequential anti-PD-(L)1 and sotorasib therapy are associated with a significantly increased risk of severe sotorasib-related hepatotoxicity and severe non-liver AEs. We suggest avoiding starting sotorasib within 30 days from the last anti-PD-(L)1 infusion.
引用
- Chour A, Denis J, Mascaux C, et al. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer. J Thorac Oncol. 2023. PMID: 37217096. doi:10.1016/j.jtho.2023.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。